Research guide
Survodutide
Dual GLP-1 receptor / glucagon receptor (GCGR) co-agonist engineered to balance incretin and glucagonergic signalling. Studied in hepatic lipid-metabolism, adipose-browning, and energy-expenditure models where the glucagon arm differentiates it from GLP-1-only agonists.
Short answer
Survodutide is supplied by HALO as a research-use-only lyophilized compound for qualified laboratory research. Dual GLP-1 receptor / glucagon receptor (GCGR) co-agonist engineered to balance incretin and glucagonergic signalling. Studied in hepatic lipid-metabolism, adipose-browning, and energy-expenditure models where the glucagon arm differentiates it from GLP-1-only agonists.
- Available sizes: 10 mg
- Documentation: 98%+ HPLC purity, independent COA, lot-indexed records
- Use limitation: Research use only; not for human or veterinary use
Diagrams
Mechanism of action in research models
Survodutide (BI-456906) is a dual agonist at two receptors: the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Unlike tirzepatide, which pairs GLP-1R with the GIP receptor, Survodutide pairs GLP-1R with GCGR — making the glucagon arm, rather than the GIP arm, the differentiating signal. Both receptors are class-B Gs-coupled GPCRs that raise intracellular cAMP on activation.
GLP-1R arm: glucose-dependent insulin secretion from pancreatic beta cells, suppression of inappropriate glucagon release, slowed gastric emptying, and central appetite suppression via hypothalamic circuits.
GCGR arm: activation of the hepatic glucagon receptor drives lipolysis and increased energy expenditure, with research interest centred on hepatic lipid handling and fat-content endpoints. The key design feature of GLP-1/glucagon co-agonists is that the GLP-1R signal glycaemically buffers the glucagon arm — co-activated GLP-1R promotes glucose-dependent insulin release, so the lipolytic and energy-expenditure effects of GCGR can be studied without the hyperglycaemia native glucagon would otherwise cause.
Why the glucagon arm matters
The glucagon receptor is the lever that distinguishes Survodutide from GLP-1 mono-agonists like semaglutide. In preclinical hepatic models the GCGR signal is associated with reduced hepatic lipid content and increased metabolic rate. This positions Survodutide as a research tool for questions about hepatic metabolism and steatosis models specifically, where a controlled glucagon-receptor signal is the variable of interest.
Dual versus triple agonism
Survodutide (GLP-1R + GCGR) and retatrutide (GLP-1R + GIPR + GCGR) both carry the glucagon arm, but retatrutide adds GIP-receptor activation. Running them side by side isolates what the GIPR arm contributes on top of a GLP-1/glucagon backbone — see the Survodutide vs Retatrutide comparison.
Identity and handling
Survodutide ships lyophilized at ≥98% HPLC purity with independent COA, in 10 mg vials. It carries an albumin-binding fatty-diacid for extended research half-life; account for albumin sequestration in serum-containing media. Reconstitute in sterile bacteriostatic water (in-vivo work) or an appropriate buffer for cell culture, and store −20 °C dry, 4 °C reconstituted ≤28 days.
Frequently asked research questions
What receptors does Survodutide activate?
How is Survodutide different from semaglutide?
How does Survodutide compare to retatrutide?
Research use only. Materials are sold strictly for in vitro and qualified laboratory research. Not for human or veterinary use, diagnosis, or treatment. Full text: Research Use Statement.